Lion Point Capital, LP — 13F Holdings & Portfolio
CIK 1643354 · latest 13F-HR filed 2026-05-15
Lion Point Capital, LP manages $16.7M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PRAX (8.57%), MLTX (7.52%), RPRX (6.14%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 4, added to 11, and trimmed 19.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$16.7M
Long-equity book
35
Distinct positions
2026-03-31
Filed 2026-05-15
+0 / −4 / ↑11 / ↓19
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- MOONLAKE IMMUNOTHERAPEUTICS$368.6K +41.4%
- ROYALTY PHARMA PLC$199.7K +24.1%
- PRAXIS PRECISION MEDICINES I$122.2K +9.3%
- GERON CORP$98.3K +12.9%
- SYNDAX PHARMACEUTICALS INC$84.6K +11.2%
Top Trims
- MILESTONE PHARMACEUTICALS IN-$549.3K -36.0%
- JASPER THERAPEUTICS INC-$443.5K -52.1%
- SERES THERAPEUTICS INC-$189.7K -40.4%
- BENITEC BIOPHARMA INC-$174.8K -20.9%
- FENNEC PHARMACEUTICALS INC-$174.3K -20.1%
Exited Positions
- DAY ONE BIOPHARMACEUTICALS I$391.4K
- VENTYX BIOSCIENCES INC$374.7K
- MINERVA NEUROSCIENCES INC$140.7K
- MERSANA THERAPEUTICS INC$2.9K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $1.4M | 8.57% | 4,450 | SH |
| 2 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $1.3M | 7.52% | 67,500 | SH |
| 3 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $1.0M | 6.14% | 21,400 | SH |
| 4 | MILESTONE PHARMACEUTICALS IN | MIST | 59935V107 | $975.8K | 5.83% | 820,000 | SH |
| 5 | GERON CORP | GERN | 374163103 | $861.2K | 5.15% | 578,000 | SH |
| 6 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $841.0K | 5.03% | 36,000 | SH |
| 7 | ARDELYX INC | ARDX | 039697107 | $770.6K | 4.61% | 128,650 | SH |
| 8 | FENNEC PHARMACEUTICALS INC | FENC | 31447P100 | $691.5K | 4.13% | 112,434 | SH |
| 9 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $660.3K | 3.95% | 62,000 | SH |
| 10 | SAREPTA THERAPEUTICS INC | SRPT | 803607100 | $620.2K | 3.71% | 28,500 | SH |
| 11 | DISC MEDICINE INC | IRON | 254604101 | $517.9K | 3.10% | 8,100 | SH |
| 12 | CUE BIOPHARMA INC | CUE | 22978P106 | $506.4K | 3.03% | 2,202,854 | SH |
| 13 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $442.4K | 2.64% | 80,000 | SH |
| 14 | BIOHAVEN LTD | BHVN | G1110E107 | $437.4K | 2.61% | 51,700 | SH |
| 15 | LANTHEUS HLDGS INC | LNTH | 516544103 | $417.2K | 2.49% | 5,500 | SH |
| 16 | JASPER THERAPEUTICS INC | JSPR | 471871202 | $407.4K | 2.44% | 465,000 | SH |
| 17 | HUMACYTE INC | HUMA | 44486Q103 | $394.4K | 2.36% | 650,000 | SH |
| 18 | VIATRIS INC | VTRS | 92556V106 | $374.2K | 2.24% | 27,700 | SH |
| 19 | KURA ONCOLOGY INC | KURA | 50127T109 | $374.0K | 2.24% | 46,000 | SH |
| 20 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $371.3K | 2.22% | 5,000 | SH |
| 21 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $326.3K | 1.95% | 18,000 | SH |
| 22 | ROCKET PHARMACEUTICALS INC | RCKT | 77313F106 | $307.9K | 1.84% | 86,000 | SH |
| 23 | PACIRA BIOSCIENCES INC | PCRX | 695127100 | $305.1K | 1.82% | 13,500 | SH |
| 24 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $286.6K | 1.71% | 9,100 | SH |
| 25 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $284.4K | 1.70% | 10,500 | SH |
| 26 | SERES THERAPEUTICS INC | MCRB | 81750R201 | $280.0K | 1.67% | 31,570 | SH |
| 27 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $264.1K | 1.58% | 19,000 | SH |
| 28 | UNIQURE NV | QURE | N90064101 | $240.3K | 1.44% | 14,700 | SH |
| 29 | REGENXBIO INC | RGNX | 75901B107 | $222.9K | 1.33% | 26,600 | SH |
| 30 | AZENTA INC | AZTA | 114340102 | $205.0K | 1.22% | 9,700 | SH |
| 31 | INNOVIVA INC | INVA | 45781M101 | $191.1K | 1.14% | 8,200 | SH |
| 32 | GH RESEARCH PLC | GHRS | G3855L106 | $143.4K | 0.86% | 10,200 | SH |
| 33 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $123.7K | 0.74% | 5,250 | SH |
| 34 | INNATE PHARMA S A | IPHA | 45781K204 | $103.9K | 0.62% | 81,151 | SH |
| 35 | SPRUCE BIOSCIENCES INC | SPRB | 85209E208 | $65.3K | 0.39% | 1,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $16.7M | 35 | 0001013594-26-000605 |
| 2025-12-31 | 2026-02-17 | $19.3M | 39 | 0001013594-26-000252 |
| 2025-09-30 | 2025-11-14 | $17.6M | 27 | 0001013594-25-001425 |